REVLIMID®

Drug Information Related Patent

Hold Company

BRISTOL MYERS SQUIBB

Learn More

Dosage and Administration

CAPSULE;ORAL

Specification

5MG; 10MG; 15MG; 25MG; 2.5MG; 20MG

Indication

REVLIMID® is suitable for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, follicular lymphoma and marginal zone lymphoma.

Use

Instructions for Use

API

LENALIDOMIDE

API Structure

We Supply

LENALIDOMIDE

Note:

In-house Standard
Facility GMP
USMF/ASMF/CDE

null

Note:

null

Note:

null

Drug Patent

Patent No	Expiration Date
8741929	2028/3/8
7855217	2024/11/24
7465800	2027/4/27

API Patent

Patent No	Expiration Date
7855217	2024/11/24
7465800	2027/4/27

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.

HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION

Tel:
E-mail:
Address:
WhatsAPP

Member of

CERTIFICATION